# A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations

> **NCT03691207** · PHASE2 · COMPLETED · sponsor: **Ayala Pharmaceuticals, Inc,** · enrollment: 87 (actual)

## Conditions studied

- Adenoid Cystic Carcinoma

## Interventions

- **DRUG:** AL101

## Key facts

- **NCT ID:** NCT03691207
- **Lead sponsor:** Ayala Pharmaceuticals, Inc,
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-14
- **Primary completion:** 2022-07-15
- **Final completion:** 2022-12-02
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2024-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03691207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03691207, "A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03691207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*